TY - JOUR
T1 - Current State of Immune-Based Therapies for Glioblastoma
AU - Lim, Michael
AU - Weller, Michael
AU - Chiocca, E. Antonio
PY - 2016
Y1 - 2016
N2 - Glioblastoma is one of the most aggressive solid tumors, and, despite treatment options such as surgery, radiation, and chemotherapy, its prognosis remains grim. Novel approaches are needed to improve survival. Immunotherapy has proven efficacy for melanoma, lung cancer, and kidney cancer and is now a focus for glioblastoma. In this article, glioblastoma-mediated immunosuppression will be discussed and two exciting immune approaches, checkpoint inhibitors and viral-based therapies, will be reviewed.
AB - Glioblastoma is one of the most aggressive solid tumors, and, despite treatment options such as surgery, radiation, and chemotherapy, its prognosis remains grim. Novel approaches are needed to improve survival. Immunotherapy has proven efficacy for melanoma, lung cancer, and kidney cancer and is now a focus for glioblastoma. In this article, glioblastoma-mediated immunosuppression will be discussed and two exciting immune approaches, checkpoint inhibitors and viral-based therapies, will be reviewed.
UR - http://www.scopus.com/inward/record.url?scp=84991383176&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84991383176&partnerID=8YFLogxK
U2 - 10.14694/EDBK_159084
DO - 10.14694/EDBK_159084
M3 - Review article
C2 - 27249715
AN - SCOPUS:84991383176
SN - 1548-8756
VL - 35
SP - e132-e139
JO - American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting
JF - American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting
ER -